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Abstract
The abundant and restricted expression of surfactant proteins SP-A and SP-D within the lung makes these collectins
specific markers for lung diseases. The measurement of SP-A and SP-D in amniotic fluids and tracheal aspirates reflects lung
maturity and the production level of the lung surfactant in infants with respiratory distress syndrome (RDS). The SP-A
concentrations in bronchoalveolar lavage (BAL) fluids are significantly decreased in patients with acute respiratory distress
syndrome (ARDS) and also in patients at risk to develop ARDS. The prominent increase of these proteins in BAL fluids and
sputum is diagnostic for pulmonary alveolar proteinosis (PAP). The concentrations of SP-A and SP-D in BAL fluids from
patients with idiopathic pulmonary fibrosis (IPF) and interstitial pneumonia with collagen vascular diseases (IPCD) are
rather lower than those in healthy controls and the SP-A/phospholipid ratio may be a useful marker of survival prediction.
SP-A and SP-D appear in the circulation in specific lung diseases. Their serum concentrations significantly increase in
patients with PAP, IPF and IPCD. The successive monitoring of serum levels of SP-A and SP-D may predict the disease
activity. The serum SP-A levels increase in patients with ARDS. SP-A is also a marker for lung adenocarcinomas and can be
used to differentiate lung adenocarcinomas from other types and metastatic cancers from other origins, and to detect
metastasis of lung adenocarcinomas. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Hydrophilic surfactant proteins A and D are
water-soluble and belong to the collectin subgroup
of the C-type lectin superfamily, along with mannose
binding lectin (MBL) and collectin-43 (CL-43) [1].
The genes of lung collectins, SP-A, SP-D, and
MBL have been mapped to human chromosome 10
[2,3]. The human SP-A and SP-D genes are placed at
10q22-q23 while MBL is localized at 10q21. Lung
collectins are synthesized by alveolar type II cells
and Clara cells within the lung. Analysis by immu-
noblot and reverse transcriptase-polymerase chain re-
action (RT-PCR) has revealed that SP-A is expressed
in the small intestine and colon but not in the stom-
ach in the rat [4], while the presence of SP-A in
human gastrointestinal tract has so far not been re-
ported. SP-D protein and mRNA have also been
detected in mucus-secreting cells of rat gastric muco-
sa by immunostaining and RT-PCR [5]. One report
shows that human stomach but not heart or liver
expresses SP-D mRNA [6], as determined by
RT-PCR. Although there are several lines of evi-
dence that pulmonary and gastrointestinal epithelium
produce closely related surface-active materials, the
expression of SP-A and SP-D is predominantly
strong in the lung.
Alterations in pulmonary surfactant may contrib-
ute to the pathogenesis of lung diseases such as res-
piratory distress syndrome (RDS), acute respiratory
distress syndrome (ARDS), interstitial lung diseases
and lung cancer. Several studies with bronchoalveo-
lar lavage (BAL) £uids in patients with idiopathic
pulmonary ¢brosis (IPF) and pulmonary alveolar
proteinosis (PAP) have demonstrated abnormalities
including the decreased recovery of surfactant phos-
pholipids, decreased content of phosphatidylglycerol,
and decreased ratio of phosphatidylglycerol (PG)/
phosphatidylinositol (PI) [7^9]. Phospholipid analysis
in amniotic £uids has also been useful to evaluate
fetal lung maturity. The determination of lecithin/
sphingomyelin ratio and disaturated phosphatidyl-
choline has been clinically practical. Primary lung
adenocarcinoma is marked by a high content of sa-
turated phosphatidylcholine, predominantly of the
dipalmitoyl species [10]. Metastatic adenocarcinomas
in the lung originating from another organ exhibit
di¡erent phospholipid pro¢les from primary lung ad-
enocarcinoma [10], suggesting phospholipid analysis
is one of the approaches to di¡erentiate lung carci-
nomas. The disadvantages of phospholipid analysis
may include a necessity for specimen quantity and
sensitivity.
The abundant and restricted expression of SP-A
and SP-D within the lung makes these collectins spe-
ci¢c markers for lung diseases. cDNAs for SP-A and
SP-D and speci¢c antibody against each protein have
been shown to be useful and sensitive tools to detect
SP-A and SP-D. Establishment of enzyme-linked im-
munosorbent assay (ELISA) for each collectin also
enables the determination of the absolute amount of
the proteins [11,12]. In this review article we discuss
the detection of SP-A and SP-D as disease markers
in various specimens. Although lung surfactant had
been believed to exist solely in the lung, SP-A and
SP-D have recently been detected in serum. Since the
detection of lung collectins in serum is expected to be
a useful and non-invasive diagnostic tool for speci¢c
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lung diseases, we discuss this issue extensively in this
review.
2. Enzyme-linked immunosorbent assay (ELISA)
2.1. Amniotic £uids
Respiratory distress syndrome (RDS) of newborn
infants is caused by lung immaturity. Fetal lung ma-
turity has been assessed by phospholipid analysis of
surfactant in amniotic £uids [13], and microbubble
stability test [14]. Determination of accurate
amounts of the apoproteins using polyclonal and
monoclonal antibodies against human SP-A, in com-
bination with phospholipid analysis [11,15], enabled
clinicians to predict lung maturity more precisely.
We have developed a two-site immunoassay of SP-
A using two monoclonal antibodies against human
SP-A [16]. In normal pregnancies, the concentration
of SP-A in the amniotic £uids at less than 30 weeks
gestation is very low (mean 0.84 Wg/ml). It then in-
creases approximately 6.5-fold from 34 to 36 weeks
of gestation and approximately 15.5-fold at 37 weeks
of gestation. This ELISA assay is a¡ected remark-
ably little by blood or meconium contamination.
Thus, it accurately predicts lung maturity [17],
although it may give a false positive result in severe
preeclampsia [18]. SP-D concentrations in amniotic
£uids increase progressively with increasing gesta-
tional age [12].
2.2. Bronchoalveolar lavage (BAL) £uids
2.2.1. Pulmonary alveolar proteinosis (PAP)
Pulmonary alveolar proteinosis (PAP) is charac-
terized by accumulation of large amounts of pulmo-
nary surfactant within the alveoli [19]. When the
supernatants of BAL £uids are analyzed after low-
speed centrifugation, both SP-A and SP-D levels are
prominently high in BAL £uids and so are surfac-
tant phospholipids [20,21]. SP-A concentrations in
BAL £uids in patients with PAP increase more
than 10-fold compared to those from healthy volun-
teers (39.3 þ 12.5 Wg/ml vs. 3.5 þ 1.1 W/ml). Although
the SP-D concentrations (0.88 Wg/ml) in BAL £uids
from healthy individuals are lower than those of SP-
A, the degree of increases of SP-D in patients with
PAP is larger (21.9-fold, 19.3 þ 9.3 Wg/ml). These
studies clearly indicate that SP-A and SP-D levels
in BAL £uids are diagnostic for PAP.
2.2.2. Pulmonary ¢brosis
The total phospholipids recovered at lavage are
reduced in patients with IPF relative to normal vol-
unteers [9]. The concentrations of SP-A and SP-D
are also signi¢cantly decreased in patients with idio-
pathic pulmonary ¢brosis (IPF) and interstitial pneu-
monia with collagen vascular disease (IPCD) [21,22].
The collectin concentrations in IPF and IPCD are
decreased by 30^50% compared to controls. McCor-
mack et al. [23] have analyzed 44 IPF patients and
33 healthy volunteers, and have concluded that the
mean SP-A/phospholipid ratio is signi¢cantly lower
in patients with IPF than in healthy volunteers
(31.8 þ 2.8 vs. 63.9 þ 6.4 Wg/Wmol) and in patients
who died within 2 years than in those who survived
(23.4 þ 2.6 vs. 37.5 þ 4.2 Wg/Wmol). The 5-year surviv-
al of patients with SP-A/PL above the median level
for all patients with IPF is more than twice that of
patients below the median (68 vs. 30%). This study
shows that the determination of SP-A in BAL £uids
in patients with IPF is not only a diagnostic marker
but also is a biochemical marker in lavage that pre-
dicts survival when SP-A is normalized to phospho-
lipid. Future analysis including SP-D determination
will address the values and meaning of SP-A/phos-
pholipid ratio in patients with an early stage of lung
¢brosis to determine if SP-A/phospholipid is a useful
marker of survival at a potentially reversible phase of
the illness.
2.2.3. Acute respiratory distress syndrome
Gregory et al. [24] analyzed the crude surfactant
pellets recovered from BAL £uids of patients with
acute respiratory distress syndrome (ARDS) and pa-
tients at risk to develop ARDS. SP-A, SP-B and
phospholipids signi¢cantly decreased in patients
with ARDS and also in patients at risk to develop
ARDS. At-risk and ARDS patients had signi¢cant-
ly decreased surfactant biophysical activity. This
study suggests that surfactant supplementation may
be a useful treatment in ARDS and that early treat-
ment with surfactant supplementation for at-risk
patients might be bene¢cial to the prevention of
ARDS.
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2.3. Tracheal aspirates
The SP-A determination in tracheal aspirates in
infants with RDS is useful to monitor the secretion
of endogenous surfactant. In placebo-treated infants
with RDS, SP-A was low on the ¢rst day of life and
increased with time as RDS resolved itself, while in
infants with RDS treated with surfactant, signi¢-
cantly higher levels of SP-A were observed by
2 days after treatment and were maintained through
at least the sixth day of life [25]. This study suggests
that endogenous surfactant secretion may be stimu-
lated by treatment with synthetic surfactant.
2.4. Sputum
One report on the SP-A determination in sputum
is available [26]. Sputum samples from three PAP
patients and twenty patients with other lung diseases
were assayed for SP-A. SP-A concentrations in spu-
tum from PAP patients were 400 times higher than in
controls. The measurement of sputum SP-A is useful
for the diagnosis of PAP and clearly less invasive in
comparison with diagnostic biopsy procedure and
bronchoalveolar lavage.
2.5. Pleural e¡usions
One cancer cell line isolated from pleural e¡usions
of patients with lung adenocarcinoma possessed
characteristics of alveolar type II cells, well-devel-
oped microvilli and cytoplasmic lamellar bodies
[27]. mRNAs for SP-A, SP-B, SP-C and SP-D were
also positively detected and the SP-A protein was
found to be secreted in this cancer cell line [28]. Since
SP-A has been immunohistochemically detected in
tumors of approximately 50% of patients with lung
adenocarcinomas [29], cancer cells that invade into
the pleural cavity in patients with lung adenocarci-
nomas may produce and secrete surfactant proteins.
The SP-A protein is detected by immunoblotting
analysis of pleural e¡usions from patients with lung
adenocarcinoma [30]. The SP-A concentrations in
pleural e¡usions from patients with lung adenocarci-
nomas are found to be more than 10 times higher
than those from lung epidermoid carcinoma, small
cell lung carcinoma, adenocarcinoma of other origins
and tuberculosis [30]. Since our preliminary study
indicates that SP-D concentrations are also high in
pleural e¡usions of patients with lung adenocarcino-
mas, the determination of SP-A and SP-D in malig-
nant e¡usions could contribute to di¡erentiating pri-
mary lung adenocarcinoma from other types of lung
carcinomas and adenocarcinomas of miscellaneous
origin.
2.6. Serum
2.6.1. Do surfactant proteins appear in the
bloodstream?
Although surfactant components had been be-
lieved to exist solely in the lung, Chida et al. [31]
suggested that surfactant proteins could be found
in sera of patients with RDS using a competitive
ELISA with polyclonal antibody against SP-A or
SP-B. A positive result for SP-A was obtained in
4 infants with RDS at 1 week of age and 1 surfac-
tant-treated infant. All sera obtained at 2 months of
age were negative for SP-A and SP-B. The speci¢c-
ities of antibodies and the presence of the surfactant
proteins in serum were not demonstrated in this
study. Since the positive reactions were determined
as relative optical density compared to control, the
absolute values of the surfactant proteins in sera
were not shown. SP-A has also been reported to
leak into the circulation in patients with ARDS
[32]. It is clear that serum proteins leak into air
spaces during severe RDS [33]. Thus, it is reasonable
that surfactant proteins leak into the vascular space
when permeability of vessel walls increases.
The ELISA with two monoclonal antibodies (PC6
and PE10) to human SP-A has been applied to the
sera of patients with interstitial lung diseases in this
laboratory [34]. The sandwich ELISA is capable of
determining an SP-A level ranging from 2^250 ng/ml
when native SP-A isolated from patients with PAP is
used as a standard [35]. Since human SP-A has been
found to contain blood group A antigenic determi-
nants [36], the criticism may be raised that monoclo-
nal antibodies PC6 and PE10 may recognize simply
group A antigen but not SP-A in the blood samples.
Monoclonal antibody (MAb-8) prepared by Stahl-
man et al. [36] actually agglutinated red cells and
immunostained a wide variety of secretory glands
and epithelium other than lungs from individuals
with A or AB blood group. Reactivity of MAb-8
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with SP-A persisted after endoglycosidase-F treat-
ment, but was lost after digestion with collagenase.
However, both PC6 and PE10 reacted with SP-A
after the digestion with endoglycosidase-F and colla-
genase. Epitope mapping by treatment with BrCN
and lysyl endopeptidase has revealed that PC6 and
PE10 recognize the peptide portion contiguous to or
near the region of the small disul¢de loop of human
SP-A CRD [37]. The immunohistochemical recogni-
tion by PC6 and PE10 is essentially speci¢c to lung
cells [38]. When serum proteins were applied to an
immunoa⁄nity column that monoclonal antibody
PE10 was covalently linked with, the isolated pro-
tein, which reacted with anti-SP-A antibody by im-
munoblotting analysis, showed a band with an appa-
rent molecular mass of 35 kDa, corresponding to the
molecular size of SP-A [34]. This sandwich ELISA
also showed a positive reaction with the fraction that
bound to a mannose-Sepharose 6B when human se-
rum was applied to the a⁄nity column (Fig. 1). Im-
munoblotting analysis revealed that the serum pro-
tein binding to the mannose-a⁄nity matrix was a
PE10-reactive protein with an apparent molecular
mass identical to that of SP-A isolated from BAL
£uids (Fig. 1, inset). Since neither PE10 nor PC6
recognize human mannose-binding lectin, the protein
binding to the a⁄nity matrix is likely to be SP-A.
Taken together, the data supports the idea that our
ELISA can detect SP-A that exists in sera.
One study [39] has experimentally demonstrated
that SP-A leaks from alveolar spaces into vessels.
Human recombinant SP-A and/or arti¢cial surfac-
tant was intratracheally injected into immature new-
born rabbits, and human SP-A in alveolar washings
and sera was monitored by ELISA with PC6 and
PE10, which do not crossreact with rabbit SP-A.
The group that intratracheally received human
SP-A and saline showed that 2.4% of the human
SP-A that was instilled into the lungs was detected
in sera by ELISA. Since the group receiving saline
alone showed no detectable human SP-A in sera, this
study demonstrates that SP-A leaks from alveolar
Fig. 1. Mannose-Sepharose 6B column chromatography of se-
rum from a patient with pulmonary alveolar proteinosis. Serum
from an alveolar proteinosis patient was applied to a mannose-
Sepharose 6B column, and the protein binding to the a⁄nity
matrix was eluted with 2 mM EDTA. Each fraction was moni-
tored at 280 nm (a) and the absorbance at 450 nm (b) ob-
tained by SP-A ELISA was also plotted. Inset shows immuno-
blotting analysis (lane b) of the fractions (Fr 24 plus 25)
binding to the a⁄nity matrix using monoclonal antibody PE10.
Lane a: molecular mass standard.
Fig. 2. The serum concentrations of SP-A in patients with vari-
ous lung diseases. The bar indicates the number of individuals
that exhibit each range of SP-A concentration.
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space into the bloodstream. When surfactant replace-
ment was performed at the same time as SP-A in-
stillation, only 0.05% of human SP-A appeared in
the circulation. This indicates that the surfactant re-
placement therapy may block alveolar-to-vascular
leakage of surfactant protein that was presumably
caused by increased permeability due to lung injury.
This is consistent with the results from surfactant-
treated infants with RDS [31]. Only one RDS infant
with surfactant replacement therapy showed positive
levels of serum SP-A, while 4 patients without sur-
factant replacement had higher SP-A levels. These
studies imply that the serum SP-A levels may re£ect
the degree of lung injury in various forms of respi-
ratory failure.
2.6.2. Serum SP-A concentrations in interstitial lung
diseases
The concentrations of SP-A in 323 healthy adults
at ages of 30-70 were examined by sandwich ELISA
with PC6 and PE10 (Fig. 2). There was no di¡erence
in SP-A concentration among the ages. The mean
value of serum SP-A was 24.6 ng/ml. There was
also no di¡erence between males and females.
The previous [34,35,40] and our recent data dem-
onstrate that the SP-A concentrations in sera from
patients with PAP and IPF were prominently high:
74 þ 45.7 ng/ml (mean þ S.D., n = 11) for PAP and
67.9 þ 42.5 ng/ml (n = 112) for IPF. These values
are statistically signi¢cant when compared to healthy
controls (P6 0.001). The serum SP-A levels of pa-
tients with pneumoconiosis, tuberculosis, di¡use pan-
bronchiolitis, bacterial pneumonia and chronic pul-
monary emphysema increase moderately but the
values are signi¢cant compared to controls. The
SP-A concentration of patients with bronchial asth-
ma and sarcoidosis are almost the same level as
healthy individuals. Patients with IPCD, collagen
vascular diseases that have pulmonary ¢brosis as a
complication, exhibit signi¢cantly higher SP-A con-
centrations in sera (55.3 þ 37.9 ng/ml, n = 36). In pa-
tients with collagen vascular diseases, pulmonary ¢b-
rosis is a chronic and progressive complication that
may lead to death. Since it is important to detect
¢brotic changes of the lung as early as possible, the
determination of serum SP-A levels could be one of
the screening methods to examine pulmonary com-
plications in patients with collagen vascular diseases.
Fig. 3. The serum concentrations of SP-D in patients with various lung diseases. The abbreviations used are: HV: healthy volunteers;
IPF: idiopathic pulmonary ¢brosis; IPCD: interstitial pneumonia with collagen vascular disease; PAP: pulmonary alveolar protein-
osis; SAR: sarcoidosis; TB: tuberculosis ; BA: bronchial asthma; BE: bronchiectasia; CPE: chronic pulmonary emphysema; DPB:
di¡use panbronchiolitis ; PN: bacterial pneumonia.
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2.6.3. Serum SP-D concentrations in interstitial lung
diseases
SP-D also appears in the circulation in patients
with interstitial lung diseases (Fig. 3). The mean
SP-D level in serum from healthy volunteers (n =
303) is 48.7 ng/ml. Although the amount of SP-D
(0.88 þ 0.13 Wg/ml) recovered in bronchoalveolar lav-
age £uids is less than that of SP-A (3.5 þ 1.1 Wg/ml)
in the alveolar space [20,21], the SP-D concentration
in serum is clearly higher than the serum SP-A con-
centrations.
Previous [21] and our recent data also demonstrate
that patients with PAP, IPF and IPCD also exhibit
signi¢cantly higher concentrations of SP-D in sera.
The absolute values of serum SP-D in these patients
are higher than those of serum SP-A; 461 vs. 74 (ng/
ml) in PAP; 339 vs. 67.9 in IPF; 208.7 vs. 56.4 in
IPCD. There are no signi¢cant increases of serum
SP-D levels in patients with bronchial asthma, bac-
terial pneumonia, di¡use panbronchiolitis and
chronic pulmonary emphysema.
Taken together with SP-A data, SP-A and SP-D in
sera could be a useful marker for PAP and IPF, and
the determination of these proteins in serum could be
a useful tool to screen pulmonary complications in
collagen vascular diseases.
2.6.4. Positivity of serum SP-A and SP-D
When the cut-o¡ values (mean þ 2 S.D. of healthy
control group) are set at 48.3 ng/ml for SP-A and at
109 ng/ml for SP-D, the positivity (86.2%) of SP-D in
IPF patients is higher than that (71.4%) of SP-A
(Fig. 4). The positivity of SP-D in PAP and IPCD
is also higher than that of SP-A. Since the values of
SP-D range more widely when compared to those of
SP-A, SP-D may be more appropriate to use as a
screening test.
2.6.5. Correlation between serum lung collectin levels
and various parameters in IPF patients
There is a very weak positive correlation between
serum levels of lung collectins and serum lactate de-
hydrogenase (LDH). Although LDH is widely used
as a serum marker for IPF, serum LDH level in-
creases in diseases other than lung diseases. Since
SP-A and SP-D are lung-speci¢c, it is clear that se-
rum SP-A and SP-D are superior to LDH as an IPF
marker. However, the serum levels of SP-A and
SP-D does not appear to be correlated with the
lung physiology which is evaluated by PaO2, vital
capacity and other lung functioning tests [21,35].
This may indicate that serum SP-A and SP-D do
not express the severity of impairment of lung func-
tion.
2.6.6. Correlation between serum collectin levels and
their disease activity
Fig. 5 shows a case with IPF in which serum levels
of SP-A and SP-D were successively monitored.
After receiving corticosteroid therapy, this patient
exhibited improvement of symptoms and chest radio-
graphic ¢ndings. Consistent with the improvement,
the levels of serum SP-A and SP-D decreased. The
levels of serum LDH appeared unchanged during
this period. However, this patient died because of
respiratory failure due to acute exacerbation with
concomitant increasing levels of serum SP-A and
SP-D.
Serum SP-D was also measured before and after
steroid therapy in 4 patients with pulmonary ¢brosis
[21]. Three IPF patients and 1 IPCD patient who had
exhibited progressive dyspnea with high levels of
SP-D (489^1906 ng/ml) before therapy improved
their symptoms and chest radiographic ¢ndings
with marked decreases of SP-D (5^25% less than
before therapy). The IPF patients who died because
of respiratory failure due to acute exacerbation
showed concomitant increasing concentrations of se-
rum SP-D levels (947^2032 ng/ml, 400^788% more
than before exacerbation). The serum SP-A levels
of 4 IPF patients also rose markedly with deteriora-
tion of the disease before their deaths [34,35]. These
Fig. 4. Positivity of serum SP-A and SP-D. The cut-o¡ values
(mean þ 2 S.D. of healthy control group) are set as 109 ng/ml
for SP-D and as 48.3 ng/ml for SP-A.
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cases suggest that the serum level of surfactant pro-
teins re£ects the disease activity of pulmonary ¢bro-
sis.
Four patients with PAP who had progressive dysp-
nea exhibited prominently high levels of serum SP-D
(239^2137 ng/ml) [21]. After therapeutic whole lung
lavages, their symptoms, chest radiographic ¢ndings
and PaO2 improved with a corresponding decrease of
serum SP-D (13^36% less than before lavage). The
serum SP-A levels of PAP patients also decreased
after therapeutic lavage with a corresponding im-
provement of symptoms [34].
2.6.7. Mechanisms by which lung collectins appear in
the circulation
The mechanisms by which SP-A and SP-D appear
in the circulation remain to be resolved. Several hy-
pothetical ones are speculated; the alteration in the
ability of surfactant production by alveolar type II
cells, the increased gradient of the apoprotein con-
centrations between the alveoli and the circulation,
the increased permeability of lung vessels, the de-
struction of the barrier between alveolar epithelium
and endothelium based on the injury of basement
membrane, and their decreased clearance rates from
the circulation. Phospholipid analysis of BAL £uids
of patients with IPF and PAP reveals decreases in
the phosphatidylglycerol/phosphatidylinositol ratio
and in the phosphatidylglycerol content [7^9]. Since
alterations in phospholipid pro¢les of surfactant re-
£ect alterations in the functions of alveolar type II
cells, this type of cells might be involved in the ap-
pearance of SP-A and SP-D in the bloodstream in
these diseases. In PAP patients, the high levels of
serum SP-A correlated well with SP-D. The contents
of SP-A and SP-D in BAL £uids are prominently
high as well as those of total proteins and phospho-
lipids. SP-A and SP-D, which alveolar spaces have
been ¢lled with, make the gradient of apoprotein
concentrations between the alveoli and the circula-
tion much greater in PAP patients than in healthy
controls. As a result, lung collectins might be leaking
out from the alveoli into the vessels in PAP patients.
The increased permeability of lung vessels may result
in alveolar-to-vascular leakage of surfactant proteins
under such conditions as RDS or ARDS. In these
diseased states serum proteins are known to leak into
alveolar space from the vessels [33]. It is reasonable
to speculate that a bidirectional £ux of proteins oc-
curs. It is likely that the mechanism of the appear-
ance of SP-A and SP-D in sera of patients with IPF
and IPCD is distinct from that in PAP or RDS.
Unlike in PAP patients, the amounts of SP-A and
SP-D in BAL £uids from patients with IPF and
Fig. 5. Clinical course and the serum concentrations of SP-A and SP-D in a patient with IPF. Serum levels of SP-A (R) and SP-D
(b), and LDH (F) were successively determined during the clinical course.
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IPCD are rather lower than those in healthy individ-
uals [20,22]. Alveolar reconstruction occurs in IPF
and IPCD, and as a result the basement membranes
in the alveolar epithelium and vessels are injured.
When the barrier between alveolar epithelium and
endothelium is consequently destroyed, surfactant
proteins produced by alveolar type II cells may
leak into the bloodstream. In addition the clearance
system of SP-A and SP-D in the circulation is also
unclear and should be investigated in future studies.
3. Immunohistochemistry and molecular biology
technique
3.1. Hyaline membrane disease
Monoclonal antibodies (PC6 and PE10) against
human SP-A have been applied for pathological ex-
amination of the lungs of infants with hyaline mem-
brane diseases [38]. These antibodies stained faint
granules in the cytoplasm of alveolar type II cells
in adult lung. A fetal lung of 20 weeks gestation
had no positive staining. A few scattered positive
cells were observed in a newborn lung of 31 weeks
gestation, and the stained cells increased progres-
sively with increasing gestational age. These ¢ndings
correspond to the pro¢le of SP-A concentrations in
amniotic £uids at increasing gestational ages [16].
These antibodies stained very few cells in the lungs
of the newborns who died of RDS, but the lungs of
newborns who died of other causes after recovery
from RDS showed many positively stained cells.
All of these cases exhibited hyaline membranes
pathologically. Hyaline membranes are a reliable
pathological criterion for the diagnosis of RDS.
However, hyaline membranes can also be observed
in pneumonia, uremic lung, ARDS and other patho-
logic states that cause alveolar destruction and exu-
dation. Thus, SP-A staining with these antibodies
could be a good pathological indicator re£ecting
the presence of surfactant and di¡erentiating hyaline
membrane diseases.
3.2. Lung adenocarcinomas
Several immunohistochemical studies have been
performed to examine the expression of SP-A in tis-
sues of lung adenocarcinomas using polyclonal and
monoclonal antibody. Thirty-three to 55% of tumor
tissue of primary lung adenocarcinomas exhibit pos-
itive reactions for SP-A staining [28,29,41^43]. No
positive reactions are observed in any other histo-
logic type of primary lung carcinomas or in meta-
static lung tumors [29] when analyzed by monoclonal
antibody PE10. The positive staining is observed not
only in the cytoplasm but also in nuclear inclusion
bodies of lung adenocarcinomas [29,41], suggesting
an abnormal proliferation of nuclear membranes
containing SP-A. When well-di¡erentiated and mod-
erately di¡erentiated adenocarcinomas were sub-
typed by light microscopic ¢ndings, Clara cell type
and mixed cell type accounted for 33% and 45%,
respectively, but type II cell type was merely ob-
served [29]. However, some cancer cells were found
to possess osmiophilic lamellar bodies and microvilli
characteristic of type II cells by electron microscopic
observations [41], suggesting that certain carcinomas
originate from type II cells. SP-A and SP-D cannot
be markers to determine the cellular origin of lung
adenocarcinomas because both proteins are synthe-
sized in Clara cells as well as type II cells. SP-C
expression is a potential tool to examine the cellular
origin of lung adenocarcinomas, since SP-C is ex-
pressed solely in alveolar type II cells [44].
Gazdar et al. [45] examined lung adenocarcinoma
cell lines by electron microscopy, immunostaining
with anti-SP-A antibody and Northern blots for sur-
factant proteins. Seven of the 17 adenocarcinoma cell
lines exhibited the presence of cytoplasmic structures
characteristic of Clara cells or of type II cells. Eight
of the nine cell lines expressed SP-A protein and/or
mRNA, while a single line expressed SP-C only after
dexamethasone induction. A type II cell phenotype
may be lost during the establishment of the cell line.
The study indicates that SP-A is one of the periph-
eral airway cell markers and that adenocarcinoma
cell lines express peripheral airway cell features.
Based on these studies, surfactant gene expression
by RT-PCR has been applied to the sensitive detec-
tion of metastatic pulmonary adenocarcinomas [46].
SP-A, SP-C, and/or SP-D transcripts were detected
in 84.6% of lymph nodes with histologically identi¢-
able metastases of lung adenocarcinomas and in
55.5% of lymph nodes that were negative for meta-
stasis by histological examination. This study indi-
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cates that micrometastasis of lymph nodes in lung
adenocarcinomas that remains undetectable by con-
ventional microscopic examination can be evaluated
by RT-PCR for surfactant proteins.
4. Conclusions and future perspectives
It is now obvious that SP-A and SP-D are speci¢c
markers for lung diseases. The measurement of SP-A
and SP-D in amniotic £uids and tracheal aspirates
evaluates lung maturity and the production of lung
surfactant in infants with RDS. The SP-A concen-
trations in BAL £uids are signi¢cantly decreased in
patients with ARDS and also in patients at risk to
develop ARDS. The prominent increase of these pro-
teins in BAL £uids and sputum is diagnostic for
PAP. The concentrations of SP-A and SP-D in
BAL £uids from patients with IPF and IPCD are
rather lower than those in healthy controls and the
SP-A/phospholipid ratio may be a useful marker of
survival prediction. SP-A and SP-D appear in the
circulation in speci¢c lung diseases. Their serum con-
centrations signi¢cantly increase in patients with
PAP, IPF and IPCD. The detection of SP-A and
SP-D in sera may be a useful and non-invasive new
diagnostic tool for these lung diseases. The successive
monitoring of serum levels of SP-A and SP-D may
predict disease activity, although they do not corre-
late with physiological lung functioning tests. SP-A
leaks into the circulation in patients with ARDS. It
would be also worthwhile to determine the concen-
trations of serum SP-D in ARDS. SP-A can be used
to di¡erentiate lung adenocarcinomas from other
types and metastatic cancers, and to detect metasta-
sis of lung adenocarcinomas.
KL-6, a MUC 1 mucin expressed on alveolar type
II cells and also on epithelial cells in other organs,
has been shown to increase in sera from patients with
IPF [47]. Unlike SP-A or SP-D, the KL-6 levels in
BAL £uids from IPF patients are also elevated. Fu-
ture work should include (i) determining how the
increases of serum SP-A and SP-D correlate with
the pathological changes of interstitial lung diseases,
(ii) clarifying the mechanism by which these proteins
increase in sera from patients with lung diseases, and
(iii) comparing the clinical usefulness among the bio-
markers including SP-A, SP-D and KL-6.
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